Market cap
₹49 Cr
Revenue (TTM)
₹78 Cr
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
49 | 17,917 | 18,587 | 15,853 | 17,589 |
Revenue (₹ Cr) |
78 | 1,842 | 3,330 | 2,383 | 2,654 |
Net Profit (₹ Cr) |
-12.46 | 308.62 | 720.77 | 700.18 | 859.38 |
Net Margin (%) |
-15.94 | 16.63 | 21.60 | 27.87 | 30.42 |
RoE (%) |
-25.08 | 11.81 | 18.93 | 18.40 | 18.58 |
Price to Earnings |
-- | 53.90 | 26.27 | 23.01 | 20.47 |
Price-To-Book |
1.02 | 6.50 | 4.48 | 4.06 | 4.01 |
Income Statement (₹ Cr)
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Operating Revenue
|
73.64 | 1,841.62 | 3,329.63 | 2,383.13 | 2,654.29 |
|
Total Income
|
74.37 | 1,855.87 | 3,337.47 | 2,512.01 | 2,825.39 |
|
Total Expenditure
|
72.98 | 1,328.95 | 2,168.88 | 1,552.50 | 1,681.39 |
|
EBITDA
|
0.65 | 512.67 | 1,160.75 | 830.63 | 972.90 |
|
Depreciation
|
6.13 | 130.47 | 285.40 | 83.19 | 57.71 |
|
EBIT
|
-5.48 | 382.20 | 875.35 | 747.44 | 915.19 |
|
Interest
|
6.71 | 49.12 | 187.51 | 0.94 | 8.91 |
|
Other Income
|
0.74 | 14.25 | 7.84 | 128.88 | 171.10 |
|
Exceptional Items
|
0.00 | 11.73 | -53.14 | 0.00 | 82.90 |
|
Profit before Tax
|
-11.45 | 359.06 | 642.54 | 875.38 | 1,160.28 |
|
Provision for Tax
|
-2.23 | 50.44 | -78.23 | 175.20 | 300.90 |
|
Profit after Tax
|
-9.22 | 308.62 | 720.77 | 700.18 | 859.38 |
Liabilities (₹ Cr)
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
56.21 | 2,757.68 | 4,144.34 | 3,902.45 | 4,385.41 |
|
Minority Interest
|
0.00 | 0.00 | -10.85 | -11.18 | 0.00 |
|
Non-Current Liabilities
|
2.39 | 363.37 | 758.48 | 55.61 | 222.21 |
|
Current Liabilities
|
133.65 | 1,016.50 | 2,681.14 | 366.06 | 685.36 |
|
Total Liabilities
|
-- | 3,310.68 | 6,865.52 | 3,207.85 | 4,911.11 |
Assets (₹ Cr)
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
50.00 | 2,763.86 | 5,578.78 | 1,528.69 | 905.21 |
|
Current Assets
|
136.38 | 1,277.15 | 1,800.86 | 2,696.84 | 4,024.56 |
|
Total Assets
|
-- | 3,310.68 | 6,865.52 | 3,207.85 | 4,911.11 |
|
Total Debt*
|
-- | 586.37 | 2,421.66 | 0.55 | 2.50 |
|
Net Current Assets
|
2.73 | 260.65 | -880.28 | 2,330.78 | 3,339.20 |
|
Contingent Liabilities
|
-- | 76.22 | 51.96 | 0.64 | 363.79 |
Cashflow (₹ Cr)
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-- | 132.27 | 1,065.01 | 432.37 | 659.75 |
|
Cash Flow from Investing Activities
|
-- | -199.13 | -79.97 | -334.73 | -71.34 |
|
Cash from Financing Activities
|
-- | 62.65 | -881.32 | -38.32 | -205.34 |
|
Net Cash Inflow / Outflow
|
-- | -4.21 | 103.72 | 59.32 | 383.07 |
Ratios
Profitability Ratios
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | 6.95 | 13.59 | 26.22 | 26.21 |
|
ROE (%)
|
-15.57 | 11.81 | 18.93 | 18.40 | 18.58 |
|
ROA (%)
|
-4.43 | 8.09 | 9.78 | 17.77 | 17.36 |
|
EBIT Margin (%)
|
-7.44 | 20.75 | 26.29 | 31.36 | 34.48 |
|
Net Margin (%)
|
-12.40 | 16.63 | 21.60 | 27.87 | 30.42 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-20.03 | 37.26 | 11.06 | 16.84 | 11.75 |
|
EBIT Growth (%)
|
-27.01 | 56.89 | 13.71 | 18.76 | 21.45 |
|
Net Profit Growth (%)
|
-13.91 | 127.86 | 60.98 | 17.44 | 2.39 |
|
EPS Growth (%)
|
-13.91 | 5.65 | 80.38 | 17.02 | 13.17 |
|
Book Value Growth (%)
|
-- | 30.63 | 10.19 | 23.77 | 17.30 |
Valuation Ratios
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-5.37 | 56.54 | 24.32 | 23.10 | 22.05 |
|
Price / Book Value
|
0.84 | 6.47 | 4.48 | 4.08 | 4.01 |
|
Dividend Yield (%)
|
0.00 | 0.07 | 0.00 | 0.38 | 1.95 |
|
EV/EBITDA
|
193.36 | 36.01 | 17.94 | 17.95 | 14.88 |
|
Market Cap (₹ Cr)
|
-- | 6,484.12 | 19,292.77 | 15,219.80 | 18,318.10 |
Solvency Ratios
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.01 | 0.08 | 0.10 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-- | 0.13 | 0.14 | 0.00 | 0.00 |
|
Current Ratio
|
1.02 | 1.26 | 0.67 | 7.37 | 5.87 |
|
Quick Ratio
|
0.73 | 0.82 | 0.49 | 5.88 | 5.23 |
|
Interest Coverage
|
-0.71 | 8.31 | 4.43 | 932.26 | 131.22 |
Operating Efficiency Ratios
| ANG Lifesciences | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
77.55 | 29.09 | 18.98 | 37.32 | 9.10 |
|
Asset Turnover
|
0.35 | 0.48 | 0.45 | 0.60 | 0.54 |
|
Receivable days
|
-- | 118.15 | 54.06 | 110.70 | 29.10 |
|
Inventory Days
|
-- | 98.29 | 32.16 | 65.86 | 69.53 |
|
Payable days
|
-- | 128.16 | 140.91 | 105.88 | 76.77 |
|
Cash Conversion Cycle
|
-- | 88.28 | -54.69 | 70.68 | 21.86 |